Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Advanced Research LLC

Neither a doctor nor a teaching hospital

Research payments

$19,249,961

328 payments

Through program year 2025, Advanced Research LLC is reported as receiving $19,249,961 in research payments, across 328 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $7,531,343 76
2024 Research $8,897,364 70
2023 Research $894,697 72
2022 Research $1,158,002 47
2021 Research $718,058 55
2020 Research $50,497 8

Breakdown

Who paid Research payments · program years 2020–2025
  1. Novartis Pharmaceuticals Corporation $15,092,791 16 payments
  2. Genentech, Inc. $1,058,124 77 payments
  3. Allergan Inc. $385,543 28 payments
  4. Ocular Therapeutix, Inc. $356,869 10 payments
  5. AbbVie, Inc. $341,993 61 payments
  6. Eli Lilly and Company $324,035 20 payments
  7. Dompe Farmaceutici S.p.A. $321,841 14 payments
  8. Alexion Pharmaceuticals, Inc. $312,937 4 payments
  9. EyePoint Pharmaceuticals US, Inc. $306,481 3 payments
  10. Celgene Corporation $162,419 2 payments
Studies the money was for Research payments · program years 2020–2025
  1. A Randomized, Participant and Investigator Masked, Placebo-Controlled, Multicenter, Proof-Of-Concept Study to Assess the Safety and Efficacy of Lnp023 (Iptacopan) in Patients With Early and Intermediate Age-Related MacUlar Degeneration $14,676,300 8 payments
  2. Ah and Imaging Biomarker Study $431,652 12 payments
  3. Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration $356,869 10 payments
  4. A 4-Week, Phase II, Multicenter, Randomized, Double-Masked, Vehicle- Controlled, Parallel Group Study With 4 Weeks of Follow-Up to Evaluate Safety and Efficacy of a new formulation of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution at two different Concentrations in patients with Dry Eye Disease (REDUCO) $321,841 14 payments
  5. A Phase 2, Double Masked, Placebo Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD) $312,937 4 payments
  6. A multicenter, open-label, single arm study in patients with open angle glaucoma or ocular hypertension who have not had previous laser trabeculoplasty treatment $308,967 17 payments
  7. A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD $297,840 2 payments
  8. A 96-Week, Two-Arm, Randomized, Single-Masked, Multi-Center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab 6 MG Compared to Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy $271,771 4 payments
  9. A Phase III Study to Evaluate Faricimab in Patients With Central Retinal Vein Occlusion $234,083 15 payments
  10. Iamd Observational Study $191,800 32 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record